{"filing":{"accession_number":"0001104659-26-116751","cik":"0001697862","ticker":"ARGX","company_name":"ARGENX SE","form":"6-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"tm2627805d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1697862/000110465926116751/tm2627805d1_6k.htm"},"events":[{"id":35987,"run_id":33176,"accession_number":"0001104659-26-116751","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This exhibit announces positive Phase 3 clinical trial results for efgartigimod (VYVGART Hytrulo) in autoimmune myositis, specifically meeting its primary endpoint with a 15.4-point improvement in Total Improvement Score versus placebo at Week 52 (p=0.0011). The announcement discloses that results will be presented as a late-breaking oral presentation at ACR Convergence 2026. While this is a clinical milestone rather than a discrete earnings release, M\u0026A activity, or governance event, it represents material operational/clinical progress for a biopharmaceutical company's pipeline that would affect investor assessment of the registrant's prospects and competitive position in the autoimmune disease market.","company_name":"ARGENX SE","ticker":"ARGX","filing_date":"2026-10-19","form":"6-K","submitted_at":null,"items":[{"id":40249,"accession_number":"0001104659-26-116751","item_number":"EX-99.1","item_title":"tm2627805d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit announces positive Phase 3 clinical trial results for efgartigimod (VYVGART Hytrulo) in autoimmune myositis, specifically meeting its primary endpoint with a 15.4-point improvement in Total Improvement Score versus placebo at Week 52 (p=0.0011). The announcement discloses that results will be presented as a late-breaking oral presentation at ACR Convergence 2026. While this is a clinical milestone rather than a discrete earnings release, M\u0026A activity, or governance event, it represents material operational/clinical progress for a biopharmaceutical company's pipeline that would affect investor assessment of the registrant's prospects and competitive position in the autoimmune disease market.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-19T13:01:38.382237+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40249,"accession_number":"0001104659-26-116751","item_number":"EX-99.1","item_title":"tm2627805d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit announces positive Phase 3 clinical trial results for efgartigimod (VYVGART Hytrulo) in autoimmune myositis, specifically meeting its primary endpoint with a 15.4-point improvement in Total Improvement Score versus placebo at Week 52 (p=0.0011). The announcement discloses that results will be presented as a late-breaking oral presentation at ACR Convergence 2026. While this is a clinical milestone rather than a discrete earnings release, M\u0026A activity, or governance event, it represents material operational/clinical progress for a biopharmaceutical company's pipeline that would affect investor assessment of the registrant's prospects and competitive position in the autoimmune disease market.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-19T13:01:38.382237+00:00","company_name":"ARGENX SE","ticker":"ARGX","filing_date":"2026-10-19"}]}